Celularity Stock Performance
| CELU Stock | USD 1.49 0.06 3.87% |
The firm shows a Beta (market volatility) of 2.02, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Celularity will likely underperform. At this point, Celularity has a negative expected return of -0.37%. Please make sure to confirm Celularity's maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Celularity performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Celularity has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:10 | Last Split Date 2024-02-29 |
1 | Acquisition by Diamandis Peter of 84746 shares of Celularity at 2.225 subject to Rule 16b-3 | 12/19/2024 |
2 | Acquisition by Berman Richard J of 67416 shares of Celularity subject to Rule 16b-3 | 01/06/2025 |
3 | Disposition of 652981 shares by Lim Kok Thay of Celularity at 2.4898 subject to Rule 16b-3 | 01/24/2025 |
4 | Acquisition by Brigido Stephen of 200000 shares of Celularity subject to Rule 16b-3 | 01/30/2025 |
5 | Disposition of 20000 shares by John Haines of Celularity subject to Rule 16b-3 | 02/14/2025 |
6 | Disposition of 10000 shares by Brigido Stephen of Celularity subject to Rule 16b-3 | 02/19/2025 |
7 | Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company | 02/24/2025 |
8 | Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio to Support Cell Therapy Manufacturing | 02/27/2025 |
| Begin Period Cash Flow | 28.8 M |
Celularity |
Celularity Relative Risk vs. Return Landscape
If you would invest 220.00 in Celularity on December 17, 2024 and sell it today you would lose (71.00) from holding Celularity or give up 32.27% of portfolio value over 90 days. Celularity is currently does not generate positive expected returns and assumes 7.7854% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of stocks are less volatile than Celularity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Celularity Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celularity's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Celularity, and traders can use it to determine the average amount a Celularity's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0481
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CELU |
Estimated Market Risk
| 7.79 actual daily | 69 69% of assets are less volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Celularity is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Celularity by adding Celularity to a well-diversified portfolio.
Celularity Fundamentals Growth
Celularity Stock prices reflect investors' perceptions of the future prospects and financial health of Celularity, and Celularity fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Celularity Stock performance.
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.73) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 105.83 M | ||||
| Shares Outstanding | 23.81 M | ||||
| Price To Earning | 3.08 X | ||||
| Price To Book | 2.14 X | ||||
| Price To Sales | 0.77 X | ||||
| Revenue | 22.77 M | ||||
| Gross Profit | 30.95 M | ||||
| EBITDA | (183.95 M) | ||||
| Net Income | (196.29 M) | ||||
| Cash And Equivalents | 42.65 M | ||||
| Cash Per Share | 0.29 X | ||||
| Total Debt | 65.42 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 0.91 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (38.69 M) | ||||
| Earnings Per Share | (100.39) X | ||||
| Market Capitalization | 36.9 M | ||||
| Total Asset | 143.89 M | ||||
| Retained Earnings | (841.79 M) | ||||
| Working Capital | (47.51 M) | ||||
About Celularity Performance
Assessing Celularity's fundamental ratios provides investors with valuable insights into Celularity's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Celularity is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 150.78 | 230.82 | |
| Return On Tangible Assets | (1.80) | (1.71) | |
| Return On Capital Employed | (2.89) | (2.74) | |
| Return On Assets | (1.57) | (1.49) | |
| Return On Equity | (5.51) | (5.24) |
Things to note about Celularity performance evaluation
Checking the ongoing alerts about Celularity for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Celularity help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Celularity generated a negative expected return over the last 90 days | |
| Celularity has high historical volatility and very poor performance | |
| Celularity may become a speculative penny stock | |
| Celularity has a very high chance of going through financial distress in the upcoming years | |
| Celularity currently holds 65.42 M in liabilities with Debt to Equity (D/E) ratio of 0.41, which is about average as compared to similar companies. Celularity has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Celularity's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 22.77 M. Net Loss for the year was (196.29 M) with profit before overhead, payroll, taxes, and interest of 30.95 M. | |
| Celularity currently holds about 42.65 M in cash with (38.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Roughly 56.0% of Celularity shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio to Support Cell Therapy Manufacturing |
- Analyzing Celularity's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Celularity's stock is overvalued or undervalued compared to its peers.
- Examining Celularity's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Celularity's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Celularity's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Celularity's stock. These opinions can provide insight into Celularity's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.